Women in China have found an innovative way to beat their government's infamous one-child policy: by taking fertility drugs.
"In the late 1970s China began limiting most couples to one child," reports CNN, "harshly punishing violators in the hope of limiting its ballooning population, which now stands at 1.3 billion."
However, there are no punishments for multiple births, and easy access to imported fertility drugs in clinics and pharmacies has led to a boom in twins and triplets.
Make mine a double, please.
What Makes This Trend Stand Out
- Increased Demand for Fertility Drugs
- Opportunities for the development and production of fertility drugs will increase as more women in China seek to beat the one-child policy.
- Rise in Multiple Births
- The growing trend of using fertility drugs in China presents opportunities for industries involved in providing products and services for multiple births, such as baby clothing, childcare, and education.
- Expanding Fertility Tourism
- The one-child policy in China has spurred a rise in fertility tourism as couples seek alternative ways to have more children, creating opportunities for industries related to travel, healthcare, and medical tourism.
Sectors Adopting This
- Pharmaceutical Industry
- The pharmaceutical industry can capitalize on the increased demand for fertility drugs in China to develop and distribute innovative solutions for aspiring parents.
- Childcare Industry
- The rise in multiple births resulting from fertility drugs in China presents disruptive innovation opportunities for the childcare industry to create specialized services and products catering to families with twins and triplets.
- Medical Tourism Industry
- The expanding fertility tourism market in China offers potential for the medical tourism industry to provide comprehensive and personalized packages for couples seeking fertility treatment options abroad.
